US 11,738,019 B2
Substituted heterocycles as antiviral agents
Joseph Panarese, Malden, MA (US); Samuel Bartlett, Brighton, MA (US); Dexter Davis, Watertown, MA (US); Nathaniel Kenton, Watertown, MA (US); and Yat Sun Or, Waltham, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by ENANTA PHARMACEUTICALS, INC., Watertown, MA (US)
Filed on Jul. 10, 2020, as Appl. No. 16/925,666.
Claims priority of provisional application 62/872,933, filed on Jul. 11, 2019.
Prior Publication US 2021/0008057 A1, Jan. 14, 2021
Int. Cl. C07D 471/22 (2006.01); A61K 31/4725 (2006.01); C07D 491/147 (2006.01); C07D 495/14 (2006.01); A61K 38/21 (2006.01); C07D 455/03 (2006.01)
CPC A61K 31/4725 (2013.01) [A61K 38/21 (2013.01); C07D 455/03 (2013.01); C07D 491/147 (2013.01); C07D 495/14 (2013.01)] 15 Claims
 
1. A compound represented by Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen or halo;
R2 is hydrogen;
R3 is hydrogen, halo, optionally substituted C3-C12 cycloalkyl, optionally substituted C3-C12 cycloalkenyl, optionally substituted 3- to 12-membered heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
A is optionally substituted 5-membered heteroaryl;
R4 is hydrogen;
R5 is hydrogen;
R6 is optionally substituted C1-C6 alkyl;
R7 is hydrogen;
R8 is hydrogen; and
W is —COOH.